Human endometrium undergoes extensive regeneration on a cyclic basis in premenopausal women and likely occurs through the contribution of stem/progenitor cells. Menopause results in the permanent cessation of menstrual cycles and is preceded by perimenopause, a period of several years in which endocrine and biological changes occur and is a period of risk for endometrial proliferative disorders. The objectives of this study were to identify endometrial mesenchymal stem cells (eMSC) and endometrial stromal fibroblasts (eSF) in endometrium of perimenopausal women and perform expression profile analysis of perimenopausal eMSC and eSF to gain insight into the biology of stem/progenitor and lineage cell populations during the transition to menopause. Endometrial tissue was collected from perimenopausal and premenopausal women (n = 9 each). Microarray analysis was performed on fluorescence-activated cell sorting-isolated eSF and eMSC, and data were validated by quantitative real-time PCR. Principal component analysis showed that cells clustered into three distinct groups in 3-dimensional space: perimenopausal eMSC and premenopausal eMSC clustered together, while perimenopausal eSF and premenopausal eSF formed two discrete clusters separate from eMSC. Hierarchical clustering revealed a branching pattern consistent with principle clustering analysis results, indicating that eMSC from premenopausal and perimenopausal women exhibit similar transcriptomic signatures. Pathway analysis revealed dysregulation of cytoskeleton, proliferation, and survival pathways in perimenopausal vs. Erikson et al., 2017, Vol. 97, No. 3 premenopausal eSF. These data demonstrate that cell populations have altered gene expression in perimenopausal vs. premenopausal endometrium, and that perimenopausal eSF had altered pathway activation when compared to premenopausal eSF. This study provides insight into aging endometrium with relevance to function in reproductively older women.
Introduction
Human endometrium undergoes extensive regeneration on a cyclic basis in response to estradiol (E2) and progesterone (P4) in premenopausal (PreM) women. This regeneration is likely to occur through the contribution of stem/progenitor cells of epithelial, mesenchymal, and endothelial lineages that aid in the regeneration of endometrium with each successive menstrual cycle [1] [2] [3] . Recently, a population of clonogenic, self-renewing, multipotent mesenchymal stem cells (MSC) co-expressing the markers cluster of differentiation 146 (CD146; melanoma cell adhesion molecule [MCAM] ) and betatype platelet-derived growth factor receptor (PDGFRB) was localized in the endometrium of PreM women [4] [5] [6] . Differential gene expression analysis of these endometrial mesenchymal stem cells (eMSC) revealed a clonogenic, multipotent cell that displayed both self-renewal pathways and the potential to differentiate into its lineage cell, the endometrial stromal fibroblast (eSF) [4] . Our group has subsequently demonstrated that eMSC are the parent cell of eSF and differentiate down the mesenchyme/fibroblast lineage in vitro [7] .
Menopause, with depletion of ovarian follicular reserve, results in the permanent cessation of menstrual cycles [8] . This is preceded by a period of up to several years in which endocrine and biological changes occur. This period is often referred to as perimenopause, and lasts from the initiation of menstrual irregularities through 1 year after the cessation of menses [9] . During this time, ovulatory cycles are common, and the endometrium becomes stimulated by excessive E2 without opposing P4 production, leading to longer menstrual cycles [10] [11] [12] . For this reason, perimenopausal (PeriM) women are said to be in a "window of risk" for endometrial proliferative disorders such as endometrial polyps, hyperplasia, and epithelial and stromal cancer due to being exposed to prolonged unopposed estrogen in a tissue that has undergone up to 350 previous proliferative cycles [13] .
With reproductive aging, postmenopausal endometrium is dormant but remains responsive to ovarian steroids, as evidenced by women undergoing hormone replacement therapy. Studies have demonstrated that reproductive aging is due to a decline in oocyte quantity as well as quality and not due to a diminished capacity of the endometrium to undergo embryo implantation [14, 15] . Recently, eMSC were found to reside in postmenopausal endometrium and did not differ significantly from eMSC isolated from PreM women [16] . However, given that the endometrium does not experience a decreased functional capacity in the proper hormonal environment, it is of interest to determine if eSF from women undergoing the transition to menopause maintain the same genotype as their PreM counterparts, if eMSC persist in a functional capacity in the endometrium during perimenopause, and whether eMSC and eSF undergo changes as a result of the changing PeriM endocrine milieu. The objectives of this study were to identify eMSC and eSF in endometrium of PeriM women and perform expression profile analysis of PeriM eMSC and eSF to gain insight into the biology of these endometrial stem/progenitor and lineage cell populations during the transition to menopause.
Materials and methods

Study subjects and tissues
Tissue samples were procured through the National Institutes of Health (NIH)/University of California, San Francisco (UCSF) Human Endometrial Tissue and DNA Bank (http://obgyn.ucsf.edu/ crs/tissue bank) in accordance with the guidelines of the Declaration of Helsinki. Written, informed consent was obtained from all participants in the UCSF Center for Reproductive Health, and the study was approved by the UCSF Committee on Human Research. The clinical summary of the study participants is shown in Table 1 . PeriM subjects (n = 94 554 yrs) had measured serum levels of antiMüllerian hormone (AMH; a predictor of ovarian reserve) at or below 0.42 ng/ml (Table 1) as measured by the University of Virginia NIH National Centers for Translation and Infertility Centers Ligand Core. One PeriM subject who did not consent to blood collection was experiencing irregular cycles while another reported regular menstrual cycles. Both were included in the study analysis based on age and inclusion verified by clustering of their respective samples by principal component analysis (PCA) and hierarchical clustering (HC) with samples from other PeriM subjects. PreM subjects (n = 9; age 24-41 yrs) reported regular menstrual cycles or featured hormonal profiles indicative of proliferative phase. All samples were obtained from women undergoing benign gynecological surgery. Neither PeriM nor PreM subjects were exposed to hormonal medications for at least 2 months prior to tissue sampling and were confirmed to be not pregnant.
Tissue processing and fluorescence-activated cell sorting of endometrial stromal cell populations Tissue biopsies were divided into separate fresh samples and processed separately for fluorescence-activated cell sorting (FACS) and histological examination in optimal cutting temperature (OCT) compound. Tissue processing for FACS analysis was performed as previously described [4, 17] 
Immunofluorescence
Immunofluorescence staining of frozen endometrial biopsy sections obtained from PeriM women to identify eMSC was performed as previously described [4] . Briefly, frozen sections ( 
Statistics
Microarray data analysis was performed using GeneSpring as previously described [4, 17] . The intensity values of probe sets in the GeneChip operating software (Affymetrix) were imported into GeneSpring version 11.02 software (Agilent Technologies), normalized and subjected to log 2 transformation using the robust multiarray analysis as the background correction algorithm for ST array technology. Pairwise comparisons of differentially expressed genes (P < 0.05, ≥1.5 FC) between different cell types or individual cell types between different age groups were performed using ANOVA with Tukey post hoc analysis and Benjamini-Hochberg multipletesting correction for false discovery rate. An unbiased PCA algorithm was applied to all samples, using all 21 014 genes on the chip to identify similar expression patterns and visualize underlying cluster structures in 3-dimensional space. HC analysis was performed using differentially expressed genes with 2.0-fold or greater change difference from all samples and among all experimental conditions. The clustering algorithm used the Euclidean distance measure with the centroid linkage rule to identify samples with similar patterns of gene expression. For post array quantitative PCR analysis, data were analyzed by analysis of variance (ANOVA) utilizing Tukey post-hoc analysis with R commander (http://socserv.mcmaster.ca/jfox/Misc/Rcmdr). For pathway analysis of biological functions, IPA was used to identify pathways that were affected by differentially expressed genes in each treatment group with a >2.0-fold change. Identified pathways were analyzed for Z-scores to assess the activation (>2.0) or inhibition (<2.0) of respective pathways [18] .
Results
Transcriptome analysis of endometrial mesenchymal stem cells and endometrial stromal fibroblast from perimenopausal and premenopausal women
The .cel files obtained from the microarray studies showing differential gene expression by age (PeriM versus PreM) and cell type (eMSC versus eSF) were uploaded to the Gene Expression Omnibus (GEO at the National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/geo/; accession number GSE97163).
Principal component analysis and hierarchical clustering of fluorescence-activated cell sorting-isolated endometrial cell populations
Five different cell populations from each sample were identified by FACS according to the fluorochrome-conjugated antibody labeling: CD45+ leukocytes, EPCAM+ ECs, CD146+/PDGFRB-endothelial cells, CD146-/PDGFRB+ eSF, and CD146+/PDGFRB+ eMSC. CD45+ and EPCAM+ cells were sorted out and not collected for the present study; only eSF and eMSC populations were analyzed herein. Analysis of microarray data from the two isolated cell types showed that they clustered into three distinct groups in 3-dimensional space by PCA ( Figure 1A ): PeriM eMSC and PreM eMSC clustered together, while PeriM eSF and PreM eSF formed discrete clusters separate from eMSC. HC revealed an initial three-way branching separating PreM eSF from eMSC and PeriM eSF. A second branching separated eMSC from PeriM eSF. Within the eMSC sub-branch, the samples did not cluster distinctly by age group (PeriM or PreM), showing no clear segregation between the eMSC populations ( Figure 1B) , consistent with the unbiased PCA results ( Figure 1A ). Tables S1-S4 ). Selected genes appear in Table 2 . Transcript cluster IDs from genes in the resultant lists were submitted for IPA analysis. The complete list of regulated biological pathways appears in Supplemental Tables  S5-S8 . From this list, pathways noted to be regulated between specific comparisons (Table 3) were used to select genes for Q-RT-PCR validation (Table 4) .
Differentially expressed genes
Resultant gene lists were generated using a 1.5-fold change threshold from the pairwise comparisons of differentially expressed genes [19] [20] [21] [22] [23] . There were 1066 differentially expressed genes in the PeriM eSF vs. PreM eSF comparison (704 up-regulated and 362 downregulated), 145 differentially expressed genes in the PeriM eMSC vs. PreM eMSC comparison (17 up-regulated, 128 down-regulated), 645 differentially expressed genes in the PeriM eSF vs. PeriM eMSC comparison (575 up-regulated, 70 down-regulated), and 656 differentially expressed genes in the PreM eSF vs. PreM eMSC comparison (297 up-regulated, 359 down-regulated). The relationship between differentially expressed genes and comparisons can be seen in Figure 2 . These data demonstrate, like the PCA and HC analyses, that the PeriM and PreM eMSC have more genes in common than PeriM eSF and PreM eSF. In addition, the number of differentially expressed genes between eSF and eMSC comparison are similar, regardless of age group (645 PeriM, 656 PreM).
Ingenuity pathway analysis
IPA was based on two metrics, activation Z-score and P-value (Supplemental Tables S5-S8 ). Pathway analysis using transcript cluster IDs from the resultant gene lists revealed a number of regulated 
biological pathways. Significant activation of a pathway was predicted with an activation Z-score > 2.0; significant suppression of a pathway was predicted with an activation Z-score <-2.0 [19] . There were 52 regulated pathways in the PeriM eSF vs. PreM eSF comparison; 46 regulated pathways in the PreM eSF vs. PreM eMSC comparison; and 75 regulated pathways in the PeriM eSF vs. PeriM eMSC comparison. There were no regulated biological pathways in the PeriM eMSC vs. PreM eMSC comparison, which is not surprising given the relatively small number of differentially regulated genes between these two groups and highlighting the similarity in gene expression of these two groups revealed by PCA and HC. A subset of regulated pathways that appeared within several comparisons was generated and is shown in Table 3 . These include organization of cytoskeleton, fibrogenesis, formation of filaments, metabolism of protein, cell spreading, formation of actin stress fibers, migration of fibroblast cell lines, cell transformation, proliferation of fibroblasts, formation of cytoskeleton, and organismal death. Table 4 . Genes were chosen for validation based on their involvement in selected significantly regulated biological pathways. A finding of note is the differential expression of a number of small nucleolar RNA C/D box (SNORD) and small nucleolar RNA H/ACA box (SNORA) genes across several different comparisons in the study (Table 5 ). These include among the most highly upregulated genes in PeriM eMSC vs. PreM eMSC (SNORD113-3, 116-1, 114-2, 114-26, and SNORA42), PeriM eSF vs. PeriM eMSC (SNORA28, 48). We also investigated estrogen receptor alpha (ESR1), estrogen receptor beta (ESR2), and progesterone receptor (PGR) by Q-RT-PCR to gain insight into the potential for ovarian hormonal regulation of eSF and eMSC. PGR was up-regulated in all eSF vs. eMSC comparisons, and up-regulated in all PeriM vs. PreM comparisons. ESR1 was down-regulated in all PeriM vs. PreM comparisons, but up-regulated in eSF vs. eMSC comparisons. ESR2 showed a more complex regulation, with highest up-regulation in PeriM eSF vs. PreM eSF and greatest downregulation in PreM eSF vs. PreM eMSC. CD146, the marker used to select between eMSC and eSF, was not differentially expressed in the array analysis, most likely due to variability in expression by eMSC collected from different subjects. Analysis with Q-RT-PCR, however, revealed an 18.6-fold down-regulation in PeriM eSF vs. PeriM eMSC and a 3106.5-fold down-regulation in PreM eSF vs. PreM eMSC as anticipated. Of note is the up-regulation of CD146 in PeriM eSF vs. PreM eSF (893.2-fold), supporting the PCA and HC data demonstrating that PeriM eSF cluster more closely to the eMSC populations than PreM eSF.
Localization of endometrial mesenchymal stem cells in perimenopausal endometrium
We previously demonstrated the localization of eMSC in the perivascular region around small blood vessels in PreM endometrium [4] . In the present study, FACS analysis revealed a population of endometrial cells that co-express CD146 and PDGFRB in PeriM endometrial tissue digests. Sections of PeriM endometrial biopsies embedded in OCT were analyzed for the presence of CD146 and PDGFRB by indirect immunofluorescence. CD146 localized to perivascular and endothelial cells in the endometrium (Figure 3) , while PDGFRB localized to both endometrial stromal cells and perivascular cells (Figure 3 ). Neither CD146 nor PDGFRB were observed in endometrial glandular epithelium. CD146+/PDGFRB+ cells were identified in the perivascular region around small blood vessels in PeriM endometrium, confirming the presence of eMSC in PeriM endometrium. These results are similar to those previously found in PreM endometrium [4, 6] , where eMSC were also localized to the perivascular region in human endometrium.
We also evaluated the ratio of eMSC:eSF in PeriM endometrium and PreM endometrium to investigate the possibility of increased numbers of eMSC in PeriM endometrium. The ratio of eMSC:eSF in PeriM endometrium (0.033 ± 0.016) was not significantly different than that of PreM endometrium (0.024 ± 0.005) following analysis by FACS (P > 0.05) (data not shown).
Discussion
Endometrial mesenchymal stem cells and endometrial stromal fibroblast in peri and premenopausal women
This report provides the first differential gene expression analysis in endometrial cell populations from women undergoing the transition to menopause compared to PreM women. In addition, we have identified eMSC in PeriM women and have gained insight into the effect of the changing hormonal milieu in vivo on endometrial cells, namely eSF and eMSC, in these women. Interestingly, our results indicate that eMSCs from PreM and PeriM women exhibit a similar transcriptomic signature, while PeriM eSF exhibit pathway changes suggesting an aging cellular phenotype compared to PreM eSF.
Peri and premenopausal endometrial mesenchymal stem cells
PCA revealed that the eMSC populations from PeriM and PreM women clustered together, and gene profiling analysis revealed that this comparison contained the fewest number of differentially expressed genes amongst those investigated in this study. Together, these data suggest that eMSC are not dramatically different from women in either age group studied herein, and that the changing hormonal environment in PeriM did not have an effect on eMSC gene expression when compared to PreM women. A recent study demonstrated that eMSC collected from postmenopausal women demonstrated similar clonogenicity, multipotency, and surface molecule phenotype whether or not, the subjects were treated with E2 prior to collection [16] . In addition, eMSC from postmenopausal women in the same study demonstrated similar self-renewal and eMSC marker expression as PreM eMSC [16] . These data support our observation that eMSC from PeriM women contain a similar transcriptome to those found in PreM women.
Peri and premenopausal endometrial stromal fibroblast PCA revealed eSF from PeriM and PreM women clustered into two distinct and separate groups from the eMSC. When comparing PeriM eSF to PreM eSF in the gene profiling analysis, the largest number of differentially expressed genes resulted from this comparison. PeriM eSF also branched more closely to the eMSC groups in the HC analysis, suggesting the PeriM eSF were more similar in gene expression profile to the eMSC than PreM eSF. Genes previously shown to be more highly expressed in eMSC than eSF from PreM women, including members of the Notch (Notch 
12. [4] are more highly expressed in PeriM eSF than PreM eSF in the present study (Table 1 ). In addition, expression of CD146, the marker that differentiates eMSC from eSF in our FACS isolation protocol, shows an almost 900-fold increase in expression in PeriM eSF vs. PreM eSF by Q-RT-PCR (Table 3 ). This data suggest that the PeriM eSF exist in a less fully differentiated state more similar to eMSC than PreM eSF. Furthermore, this study identifies enhanced survival characteristics in the eSF from PeriM women, which may have important implications for endometrial pathologies in women later in life.
Steroid hormone receptors
In the endometrium, eSF regulate EC proliferation and differentiation during development, and one of the eSF's main roles in adult endometrium is to regulate effects of E2 on EC [24] , with eSF dysfunction potentially affecting epithelial function. While a previous study did not find any changes in hormone receptor expression in menopausal eMSC [16] , and we did not find these changes by microarray analysis, we did identify differences in ESR1, ESR2, and PGR expression by Q-RT-PCR. Progesterone receptor showed consistent patterns across comparisons, being more highly expressed in eSF than eMSC independent of age group (Table 3) . However, the fold change was greatest in PeriM eMSC vs. PreM eMSC (22.2) and PeriM eSF vs. PreM eSF (17.2) . This could be due to the effect of an inadequate opposition of E2 on the endometrium by P4, due to the lengthening and irregular menstrual cycles often seen during the transition to menopause [10] [11] [12] , perhaps resulting in an E2-stimulated increase in PGR expression [25, 26] . The differential expression of ESR1 and ESR2 revealed upregulation in eSF vs. eMSC (5.0 in PeriM; 13.4 in PreM), perhaps suggesting that fully mature eSF acquire the ability to respond to E2 during differentiation from the progenitor eMSC. Endometrial MSC (W5C5+ cells) isolated from postmenopausal endometrium did not express ERα and did not respond to systemic estrogen prior to sampling [16] , suggesting that E2 may act on eMSC through surrounding niche cells [27] . Our data support these observations; while we did not investigate ESR1 or ESR2 expression on eMSC niche cells, we did see decreased gene expression of ESR1 in PeriM vs. PreM in both eMSC (-1.4-fold change) and eSF (-3.8-fold change). ESR2, on the other hand, is expressed in developing uterine tissues [28] and in vascular endothelium of adult endometrium [29] . To our knowledge, there has not been a previous report of ESR2 expression in eMSC. In the current study, we found a significant increase in differential expression of ESR2 in PeriM vs. PreM eSF (14.7). While we cannot deduce much about the expression levels or activity of this receptor based on these differential expression data, the observation is nonetheless intriguing. There is evidence that ESR2 plays a role in some uterine diseases such as endometriosis [30] and leiomyoma [31] and may play a role in uterine elasticity in postmenopausal women [28] .
The role of ESR1 and ESR2 in the PreM and PeriM endometrium with regard to eMSC and eSF function is, however, unclear and warrants further investigation. In sum, these data argue for PeriM eSF having characteristics of senescent cells that may affect the way eSF and eMSC respond to the changing hormonal environment in perimenopause.
Pathway analyses
The similarity of PeriM eSF to eMSC is further indicated by pathways revealed by IPA, including predicted activation for formation of filaments, formation of cytoskeleton, organization of cytoskeleton, and formation of actin stress fibers. Recent work has demonstrated that MSC differentiation is highly dependent upon mechanical forces affecting the cell, and that in vitro regulation of these forces can affect changes upon the cytoskeleton to drive differentiation down osteogenic, chondrogenic, and adipogenic lineage pathways [32] . While these observations in and of themselves do not constitute evidence for an eMSC-like phenotype for the PeriM eSF, they do suggest that PeriM eSF have the potential to respond to mechanical forces similar to MSC, and may exist in a less-differentiated state in the PeriM endometrium. This may also explain, in part, why PeriM eSF exhibit an anti-apoptotic phenotype compared to PreM eSF.
Among our findings are regulated pathways and differentially expressed genes that are suggestive of a population of senescent cells or cells similar to senescent cells. Cellular senescence is the growth arrest that occurs in cells when they are exposed to oncogenic stress and is a mechanism to prevent the proliferation of potential cancer cells [33] . While the transcriptome of the PeriM eSF in the current study does not wholly represent that of a senescent cell population, the downregulation of organismal death pathways (Table 2) , increased matrix metalloproteinase (MMP) expression (Table 1) , and increased EGFR expression (Table 1 ) are all common with senescent or aging cells [33] . These pathways also have overlap with age-related changes in tissues that make them more permissive to tumor growth [33] .
Small nucleolar RNAs
Gene profile analysis revealed a number of small nucleolar RNAs in the lists of differentially expressed genes by comparison ( Table 4 ). The small nucleolar RNAs act as guide RNAs for chemical modification of ribosomal, transfer, and small nuclear RNAs and are found in two classes: H/ACA box (SNORA) associated with methylation and C/D box (SNORD) associated with pseudouridylation. They are emerging as important regulators of cellular function and disease development. Noncoding RNAs, including SNORAs/SNORDs have recently drawn interest for their roles in cellular carcinogenicity [34] . While the exact roles of the specific SNORAs/SNORDs identified in the current study remain largely undefined, a growing number of these molecules has been found to exhibit differential expression patterns in a number of cancers and demonstrate roles in cell transformation, tumorigenesis, and cellular metastasis [34] . In addition, SNORAs have been found to act in tumor suppression pathways, and may be capable of modifying the expression and function of p53, a tumor suppressor gene that is the most common target of genetic modification in cancer [34] [35] [36] . Of interest in our data, is the differential expression by comparison of the SNORA/SNORD molecules (Table 4 ) and the inverse fold changes found based on PreM or PeriM status. For example, SNORD116-1 is decreased in PeriM eSF vs. PreM eSF (-2.2) and PeriM eSF vs. PeriM eMSC (-3.6), but increased in PeriM eMSC vs. PreM eMSC (2.6) and PreM eSF vs. PreM eMSC (1.7). While there is currently no report of noncoding RNAs acting to affect carcinogenic changes in PeriM or postmenopausal endometrium, it is possible that the differential expression of the SNORA/SNORD molecules is involved in altered regulation of RNA methylation and pseudouridylation in eSF and eMSC as the endometrium is transitioning to menopause. However, the significance behind these differential expressing patterns is unclear. A recent study on aging cartilage also identified a large number of differentially expressed SNORA molecules, but the authors were also unable to draw a conclusive link between the aging cells and differential expression of these molecules [37, 38] . The observation of differential expression of SNORA molecules in the current study provides an interesting avenue of study of aging endometrial function, including pregnancy establishment, maintenance, placentation, and endometrial cancer.
Role of uterine pathologies
The contribution of uterine pathologies to differences in gene expression between PeriM and PreM eSF is also worthy of discussion. Previous studies from our laboratory demonstrate gene expression differences in eMSC and eSF with the presence of pelvic inflammatory disease, namely polysystic ovary syndrome and endometriosis [7, 17] . For this reason it is not possible to rule out uterine pathologies as a contributing cause of gene expression differences in the current study. However, there were subjects from both the PeriM and PreM groups that had uterine pathologies present, which may have mitigated the effect of these pathologies on gene expression differences between age groups.
Conclusions
In this study, we have identified eMSC in women undergoing the transition to menopause and have evaluated gene expression of eMSC and eSF from PeriM women compared to PreM women. Our major finding that eSF from PeriM demonstrate a distinct gene profile from PreM eSF, while eMSC from PreM and PeriM women are quite similar, suggests that the changing hormonal milieu during the transition to menopause has a demonstrable effect on eSF gene expression and a minimal effect on the eMSC population. These data provide insight into these endometrial cell populations during the transition to menopause and offer a window into the mechanisms by which the endometrium maintains functional capacity even after menopause and potentially predisposing to abnormalities with compromised eSF functions in modulating E2 actions and other regulatory mechanisms.
We hypothesized that despite the changing hormonal milieu of the PeriM endometrium, eSF maintain functional capacity similar to PreM eSF. Our findings indicate, however, that PeriM eSF resemble more eMSC in gene signature than they do PreM eSF. This would suggest that the ability of the PeriM eSF to function in a similar manner to PreM eSF is impaired and additional studies to determine how PeriM eSF respond to sex hormones need to be performed. Analysis of the subject information in Table 1 reveals that PeriM subjects are on average older (47.9 yrs vs. 32.4 yrs, P < 0.001) and have lower average AMH levels (0.22 vs. 4.08 ng/ml, P < 0.01), with no significant differences in body mass index or circulating E2 and P4 levels. As circulating AMH levels tend to be lower in menopausal women, we can presume that these women are truly PeriM given that several have reported irregular menstrual cycles. However, we do not know the regularity of the cycles and only have a snapshot of hormonal data at a single point during the menstrual cycle in these women; we do not know for sure if the differences in gene expression observed in PeriM vs. PreM eSF are due to a differential stimulation of the cells by sex hormones in PeriM women or if these are the cumulative effects of hormone variation during irregular menstrual cycles. This needs to be addressed experimentally in the future. The apparent reduced differentiation of the PeriM eSF may also predispose the cells to variable response to hormone stimulation compared to PreM eSF, potentially leading to endometrial abnormalities in menopause. This idea also needs to be investigated further, using direct hormone stimulation of eSF from PeriM women in order to better understand the function of the PeriM eSF.
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